Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BPX-601 in Advanced Prostate Cancer
NCT02744287Phase 1Terminated
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Nov 2016
- Primary completion
- Mar 2023
- Modality
- Gene Editing, Prophylactic Vaccines, Gene Silencing
- Countries
- 1
01
Overview
Phase 1, open-label trial of BPX-601 in metastatic castration-resistant prostate cancer (mCRPC) (2 arms), sponsored by Regeneron Pharmaceuticals. Primary endpoints: Dose Limiting Toxicity at 35 days, Treatment emergent adverse events and serious adverse events at 15 years and 1 more. Started Nov 2016; status: terminated.
02
Drugs
BPX-601
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT02744287.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02744287.